Turning Point Therapeutics, Inc.
Macrocyclic compounds and uses thereof
Last updated:
Abstract:
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
Status:
Grant
Type:
Utility
Filling date:
26 Jul 2018
Issue date:
29 Mar 2022